Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevidoplenib in Persistent and Chronic Immune Thrombocytopenia
NCT04056195Phase 2Completed
- Sponsor
- Oscotec Inc.
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cevidoplenib in immune thrombocytopenia (ITP), sponsored by Oscotec Inc.. Started Oct 2019; status: completed.
02
Drugs
cevidoplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04056195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056195.